Abstract
Neuroendocrine prostate cancer is a rare entity with a poor prognosis. It can present in a pure form (small or large cell neuroendocrine carcinoma) or mixed, that is to say associated with an adenocarcinomatous contingent. Rarely diagnosed de novo, primary large cell tumors are exceptional. The development of molecular analysis tools has provided important elements for understanding the origin of this histological subtype and the signaling pathways involved. This could also help to identify diagnostic and prognostic biomarkers as well as potential molecular targets. We report here the case of a 63-year-old patient diagnosed with mixed prostate cancer with large cell neuroendocrine component at a localized stage and detail the particularities of his management.
Users
Please
log in to take part in the discussion (add own reviews or comments).